Please read full Prescribing
for NUPLAZID, including Boxed WARNING.


help & support.


The information and tools here can be important resources in securing treatment for your patients or residents, and getting them started on that treatment right away.


prescribing through an EHR system.

If you choose to e-prescribe, your patients can still get the benefits of Acadia Connect®. Simply complete the Treatment & Service Request Form available in the EHR system.

NUPLAZID® can only be filled through the following in-network pharmacies:


ordering at a long-term care (LTC) facility.

To order NUPLAZID, simply follow the current prescribing protocol for your facility.


formulary lookup.

Check NUPLAZID approvals by your patient’s insurance provider to get a better sense of the cost and coverage options available to them.




prior authorization.

Complete prior authorization that may be necessary to secure NUPLAZID coverage with your patient’s insurance provider.




This information is intended as a guide. Coverage and costs may differ between private and government insurance plans, and are subject to change. Please check with the health plan to confirm coverage for individual patients.

for you and your staff:


Treatment & Service Request Form

Prescribe NUPLAZID, request a free 14-day supply, and enroll your patients or residents in Acadia Connect by completing this form online or by downloading it below and filling out the PDF.

Sample Treatment & Service Request Form

Have questions or need help filling out the Treatment & Service Request Form? Download an annotated form with prefilled fields and directions to assist you.


Letter of Medical Necessity

Please use the template letter below to provide an outline of your patient's medical history and diagnosis when requesting coverage for NUPLAZID.



Letter of Appeal

Please use the template letter below to provide an outline of your patient’s medical history and diagnosis when requesting reconsideration for prior authorizations for NUPLAZID.



Patient Access Manager (PAM)

A PAM can assist your office in navigating payer coverage, clarifying insurance requirements, and resolving patient access issues. They will keep you informed on your patients' insurance status and any financial assistance options they may have. Additionally, they will inform you of any interruptions in your patients' treatment regimens.


for your patients or residents:


Acadia Connect Brochure

The Acadia Connect brochure is a valuable resource for sharing important program support information with your patients or residents.



Care Coordinator

The Care Coordinator works with a patient's pharmacy to get their prescriptions filled and delivered to their preferred location. Care Coordinators also help patients and caregivers with insurance processes and inform them of any financial aid opportunities.



This fact sheet contains key insights about NUPLAZID that may be helpful for your patients or residents.


For more information and downloadable resources for your patients or residents about NUPLAZID, visit the NUPLAZID Resource Library.


enroll your patients or residents.

To start these services for you and your patients or residents, complete our simple online prescription and enrollment form.

Connect with us:
8:00 am to
8:00 pm ET
Important Safety Information and Indication for NUPLAZID® (pimavanserin)


  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease.
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation
    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
  • Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
  • Drug Interactions:
    • Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.